肝细胞癌
微小残留病
癌症研究
免疫系统
疾病
巨噬细胞
逃避(道德)
生物
医学
免疫学
病理
体外
遗传学
白血病
作者
L Lemaître,Nia Adeniji,Akanksha Suresh,Reshma Reguram,Josephine Zhang,Jangho Park,A.Krishna Reddy,Alexandro E. Trevino,Aaron T. Mayer,Anja Deutzmann,Aida S. Hansen,Ling Tong,Vinodhini Arjunan,Neeraja Kambham,Brendan C. Visser,Monica M. Dua,Clark A. Bonham,Nishita Kothary,H. Blaize D’Angio,Ryan Preska
出处
期刊:Nature cancer
[Nature Portfolio]
日期:2024-09-20
卷期号:5 (10): 1534-1556
被引量:39
标识
DOI:10.1038/s43018-024-00828-8
摘要
Hepatocellular carcinoma (HCC) frequently recurs from minimal residual disease (MRD), which persists after therapy. Here, we identified mechanisms of persistence of residual tumor cells using post-chemoembolization human HCC (n = 108 patients, 1.07 million cells) and a transgenic mouse model of MRD. Through single-cell high-plex cytometric imaging, we identified a spatial neighborhood within which PD-L1 + M2-like macrophages interact with stem-like tumor cells, correlating with CD8+ T cell exhaustion and poor survival. Further, through spatial transcriptomics of residual HCC, we showed that macrophage-derived TGFβ1 mediates the persistence of stem-like tumor cells. Last, we demonstrate that combined blockade of Pdl1 and Tgfβ excluded immunosuppressive macrophages, recruited activated CD8+ T cells and eliminated residual stem-like tumor cells in two mouse models: a transgenic model of MRD and a syngeneic orthotopic model of doxorubicin-resistant HCC. Thus, our spatial analyses reveal that PD-L1+ macrophages sustain MRD by activating the TGFβ pathway in stem-like cancer cells and targeting this interaction may prevent HCC recurrence from MRD.
科研通智能强力驱动
Strongly Powered by AbleSci AI